{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:42:41Z","timestamp":1790419361277,"version":"4.1.0"},"reference-count":30,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2019,8,5]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The current guidelines suggest alcohol septal ablation (ASA) is less effective in hypertrophic obstructive cardiomyopathy (HOCM) patients with severe left ventricular hypertrophy, despite acknowledging that systematic data are lacking. Therefore, we analysed patients in the Euro-ASA registry to test this statement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We compared the short-term and long-term outcomes of patients with basal interventricular septum (IVS) thickness &lt;30 mm Hg to those with \u226530 mm Hg treated using ASA in nine European centres.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1519 patients (57\u00b114 years, 49% women) with symptomatic HOCM were treated, including 67 (4.4%) patients with IVS thickness \u226530\u2009mm. The occurrence of short-term major adverse events were similar in both groups. The mean follow-up was 5.4\u00b14.3 years and 5.1\u00b14.1 years, and the all-cause mortality rate was 2.57 and 2.94 deaths per 100 person-years of follow-up in the IVS &lt;30\u2009mm group and the IVS \u226530\u2009mm group (p=0.047), respectively. There were no differences in dyspnoea (New York Heart Association class III\/IV 12% vs 16%), residual left ventricular outflow tract gradient (16\u00b120 vs 16\u00b116\u2009mm Hg) and repeated septal reduction procedures (12% vs 18%) in the IVS &lt;30\u2009mm group and IVS \u226530\u2009mm group, respectively (p=NS for all).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The short-term results and the long-term relief of dyspnoea, residual left ventricular outflow obstruction and occurrence of repeated septal reduction procedures in patients with basal IVS \u226530 mm is similar to those with IVS &lt;30mm. However, long-term all-cause and cardiac mortality rates are worse in the \u226530 mm group.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2019-315422","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T17:24:22Z","timestamp":1567185862000},"page":"462-466","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Alcohol septal ablation in patients with severe septal hypertrophy"],"prefix":"10.1136","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3597-3155","authenticated-orcid":false,"given":"Josef","family":"Veselka","sequence":"first","affiliation":[{"name":"Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Jensen","sequence":"additional","affiliation":[{"name":"Unit for Inherited Cardiac Diseases, Department of Cardiology, Copenhagen University Hospitalet Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Liebregts","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospitalen Nieuwegein, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Cooper","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Januska","sequence":"additional","affiliation":[{"name":"Cardiocentre Podlesi, Trinec, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-4817","authenticated-orcid":false,"given":"Maksim","family":"Kashtanov","sequence":"additional","affiliation":[{"name":"Ural Federal University, Sverdlovsk, Russian Federation"},{"name":"Yekaterinburg Regional Hospital No.1, Yekaterinburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Dabrowski","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Riis","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gentofte Hospital, Copenhagen University Hospital, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Seggewiss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Juliusspital Wuerzburg, Wuerzburg, Germany"},{"name":"Clinic for General and Interventional Cardiology, Heart and Diabetes Centre NRW Ruhr-University Bochum, Bad Oeynhausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hansvenclova","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bundgaard","sequence":"additional","affiliation":[{"name":"Unit for Inherited Cardiac Diseases, Department of Cardiology, Copenhagen University Hospitalet Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospitalen Nieuwegein, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Hilton Stables","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Faber","sequence":"additional","affiliation":[{"name":"Clinic for General and Interventional Cardiology, Heart and Diabetes Centre NRW Ruhr-University Bochum, Bad Oeynhausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"2025092000182145000_106.6.462.1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309952"},{"key":"2025092000182145000_106.6.462.2","doi-asserted-by":"crossref","unstructured":"Pelliccia F , Niccoli G , Gragnano F , et al . Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a contemporary reappraisal. EuroIntervention 2019. doi:doi:10.4244\/EIJ-D-18-00959. [Epub ahead of print: 12 Mar 2019].","DOI":"10.4244\/EIJ-D-18-00959"},{"key":"2025092000182145000_106.6.462.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.10.013"},{"key":"2025092000182145000_106.6.462.4","first-page":"RA62","article-title":"Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature","volume":"13","author":"Veselka","year":"2007","journal-title":"Med Sci Monit"},{"key":"2025092000182145000_106.6.462.5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10741-018-9706-z","article-title":"Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results","volume":"23","author":"Rigopoulos","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2025092000182145000_106.6.462.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"2025092000182145000_106.6.462.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318223e2bd"},{"key":"2025092000182145000_106.6.462.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv693"},{"key":"2025092000182145000_106.6.462.9","doi-asserted-by":"crossref","first-page":"f198","DOI":"10.1093\/europace\/eux251","article-title":"Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation","volume":"20","author":"Liebregts","year":"2018","journal-title":"Europace"},{"key":"2025092000182145000_106.6.462.10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/ehjqcco\/qcy049","article-title":"Effect of impaired cardiac conduction after alcohol septal ablation on clinical outcomes: insights from the Euro-ASA registry","volume":"5","author":"Jensen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025092000182145000_106.6.462.11","first-page":"16","article-title":"Effect of institutional experience on outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy","volume":"34","author":"Veselka","year":"2018","journal-title":"Can J Cardiol"},{"key":"2025092000182145000_106.6.462.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31321-6"},{"key":"2025092000182145000_106.6.462.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.064"},{"key":"2025092000182145000_106.6.462.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.073"},{"key":"2025092000182145000_106.6.462.15","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-0962"},{"key":"2025092000182145000_106.6.462.16","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.25236"},{"key":"2025092000182145000_106.6.462.17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309699"},{"key":"2025092000182145000_106.6.462.18","doi-asserted-by":"publisher","DOI":"10.1253\/circj.70.1550"},{"key":"2025092000182145000_106.6.462.19","first-page":"1245","article-title":"Risk and causes of death in patients after alcohol septal ablation for hypertrophic obstructive cardiomyopathy","volume":"31","author":"Veselka","year":"2015","journal-title":"Can J Cardiol"},{"key":"2025092000182145000_106.6.462.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.076257"},{"key":"2025092000182145000_106.6.462.21","first-page":"99","article-title":"Effectiveness of alcohol septal ablation in obstructive hypertrophic cardiomyopathy with versus without extreme septal hypertrophy","volume":"28","author":"Yang","year":"2016","journal-title":"J Invasive Cardiol"},{"key":"2025092000182145000_106.6.462.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006153422403"},{"key":"2025092000182145000_106.6.462.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht439"},{"key":"2025092000182145000_106.6.462.24","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eup431"},{"key":"2025092000182145000_106.6.462.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04005-8"},{"key":"2025092000182145000_106.6.462.26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.eurheartj.a059689","article-title":"Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant?","volume":"11","author":"Romeo","year":"1990","journal-title":"Eur Heart J"},{"key":"2025092000182145000_106.6.462.27","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003214","article-title":"Influence of septal thickness on the clinical outcome after alcohol septal ablation in hypertrophic cardiomyopathy","volume":"9","author":"Jensen","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"2025092000182145000_106.6.462.28","first-page":"83","article-title":"Choice of septal reduction therapies and alcohol septal ablation","volume":"37","author":"Fifer","year":"2019","journal-title":"Cardiol Clin"},{"key":"2025092000182145000_106.6.462.29","first-page":"1","article-title":"Historical perspectives in the evolution of hypertrophic cardiomyopathy","volume":"37","author":"Panza","year":"2019","journal-title":"Cardiol Clin"},{"key":"2025092000182145000_106.6.462.30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-018-1209-3","article-title":"Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy","volume":"107","author":"Burghardt","year":"2018","journal-title":"Clin Res Cardiol"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2019-315422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T07:18:32Z","timestamp":1758352712000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2019-315422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,2,25]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/heartjnl-2019-315422"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2019-315422","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]}}}